Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | CEPT1 | Q9Y6K0 | 7/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 6/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225216 | 0.92 | S1PR1 (0.69) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL14797013 | 0.86 | S1PR1 (0.57) | S1PR1MAPTLMNARXFP1 | |
| SCHEMBL2224059 | 0.85 | S1PR1 (0.51) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL14796982 | 0.85 | S1PR1 (0.67) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL14797108 | 0.85 | S1PR1 (0.70) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL14797105 | 0.85 | S1PR1 (0.65) | S1PR1CEPT1CETP | |
| SCHEMBL2225593 | 0.85 | S1PR1 (0.52) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL15310051 | 0.84 | S1PR1 (0.54) | S1PR1MAPTLMNARXFP1CEPT1 | |
| SCHEMBL14797136 | 0.84 | S1PR1 (0.71) | S1PR1MAPTRXFP1CEPT1TP53 | |
| SCHEMBL14797015 | 0.84 | S1PR1 (0.74) | S1PR1MAPTLMNARXFP1CEPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846690-B2 | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| EP-2523960-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-10-16 | — | — | EP | disclosed |
| US-20130072502-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| EP-2523960-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086080-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072502-A1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | OXGR1, EDNRA, EDF1 | S1PR1 250/4885MAPT 4542/4885LMNA 4172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.